Management of metformin-induced gastrointestinal problems

Management of metformin-induced gastrointestinal problems by pharmacological and non-pharmacological treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN40695995

Enrollment

300

Registered

2018-07-10

Start date

2017-06-01

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metformin gastrointestinal adverse effects Not Applicable

Interventions

The first phase is a quantitative study in which a cross sectional research design was used. In this study patients having type 2 diabetes using metformin of different doses (500 mg, 850 mg and 100 mg

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male and female aged 26-85 years 2. Patients diagnosed with Type 2 diabetes 3. Patients using metformin

Exclusion criteria

Exclusion criteria: 1. Type 1 diabetes patients 2. Patients under 26 and older than 85 years 3. Patients who were not taking metformin 4. Patients on insulin therapy alone

Design outcomes

Primary

Measure	Time frame
GI symptoms measured by interview at baseline and 1 month	—

Secondary

Measure	Time frame
Blood sugar level measured at baseline and 1 month	—

Countries

Pakistan

Contacts

Public ContactMadeeha;Saleha Fatima;Sadeeqa

;

;;

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026